Ivan Hyep Sells 605 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 605 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $18.15, for a total transaction of $10,980.75. Following the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,638,193.25. The trade was a 0.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.55, for a total transaction of $330,097.25.
• On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.23, for a total value of $116,945.45.
• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX traded down $0.42 during trading on Tuesday, hitting $18.46. 1,136,579 shares of the stock were exchanged, compared to its average volume of 608,772. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.24 and a beta of -0.76. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $22.67. The company’s fifty day simple moving average is $15.59 and its 200-day simple moving average is $12.69.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, research analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its holdings in shares of Bicara Therapeutics by 4.1% in the first quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock valued at $371,000 after purchasing an additional 1,119 shares in the last quarter. Legal & General Group Plc boosted its position in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Bicara Therapeutics by 4.8% in the 1st quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after buying an additional 1,924 shares during the period. Finally, Invesco Ltd. raised its position in shares of Bicara Therapeutics by 13.2% during the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after acquiring an additional 1,962 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BCAX shares. Piper Sandler started coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Monday, November 10th. HC Wainwright lowered their price objective on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, August 22nd. Finally, Wells Fargo & Company increased their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.67.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.